Sustained-release drug delivery system with exosome loaded with curcumin nano-particles and application of sustained-release drug delivery system
The invention discloses a sustained-release drug delivery system of exosome loaded curcumin nano-particles and application of the sustained-release drug delivery system. Belongs to the technical field of biological medicine. The preparation method comprises the following steps: transfecting curcumin solid lipid nanoparticles Cur-SLN to human bronchial epithelial cells BEAS-2B by adopting an active loading method, and then collecting the exosome Cur-SLN-Exo by adopting an improved ultracentrifugation method. The Cur-SLN-Exo targeted small airway deposition after inhalation administration, and due to the homology of the target cell source exosome and the body cell, the body circulation system can be prevented from being cleared, so that the loaded medicine is not degraded in the extracellular environment; the lipid and protein with special structures on the surface can be quickly fused with target cells after being combined with the target cells, loaded drugs can be delivered into the cells, and compared with a lipid nano drug delivery system, the drug loading capacity can be improved, the drug delivery frequency and dosage can be reduced, the lung action time can be prolonged, and a treatment scheme is provided for COPD mitochondrial injury..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 15. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LI NAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-09-15, Last update posted on www.tib.eu: 2023-12-12, Last updated: 2023-12-15 |
|---|
| Patentnummer: |
CN116747205 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018755909 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018755909 | ||
| 003 | DE-627 | ||
| 005 | 20231215095709.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231215s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018755909 | ||
| 035 | |a (EPA)CN116747205 | ||
| 035 | |a (EPA)87958628 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LI NAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sustained-release drug delivery system with exosome loaded with curcumin nano-particles and application of sustained-release drug delivery system |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-09-15, Last update posted on www.tib.eu: 2023-12-12, Last updated: 2023-12-15 | ||
| 520 | |a The invention discloses a sustained-release drug delivery system of exosome loaded curcumin nano-particles and application of the sustained-release drug delivery system. Belongs to the technical field of biological medicine. The preparation method comprises the following steps: transfecting curcumin solid lipid nanoparticles Cur-SLN to human bronchial epithelial cells BEAS-2B by adopting an active loading method, and then collecting the exosome Cur-SLN-Exo by adopting an improved ultracentrifugation method. The Cur-SLN-Exo targeted small airway deposition after inhalation administration, and due to the homology of the target cell source exosome and the body cell, the body circulation system can be prevented from being cleared, so that the loaded medicine is not degraded in the extracellular environment; the lipid and protein with special structures on the surface can be quickly fused with target cells after being combined with the target cells, loaded drugs can be delivered into the cells, and compared with a lipid nano drug delivery system, the drug loading capacity can be improved, the drug delivery frequency and dosage can be reduced, the lung action time can be prolonged, and a treatment scheme is provided for COPD mitochondrial injury. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a KONG LINGYU |4 aut | |
| 700 | 0 | |a YANG PING |4 aut | |
| 700 | 0 | |a LI XU |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 15. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:15 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87958628/publication/CN116747205A1?q=CN116747205 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 15 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 15 |c 09 | ||